Immunotherapy for the prevention of atherosclerotic cardiovascular disease: Promise and possibilities

Atherosclerosis
Jay KhambhatiLaurence Sperling

Abstract

Cardiovascular disease remains the leading cause of death worldwide with coronary atherosclerotic heart disease being the largest contributor. The mechanisms behind the presence and progression of atherosclerosis remain an area of intense scientific focus. Immune dysregulation and inflammation are key contributors to the development of an atherosclerotic plaque and its progression to acute coronary syndromes. Increased circulating levels of biomarkers of systemic inflammation including hsCRP are correlated with a higher cardiovascular risk. Targeting specific inflammatory pathways implicated in atherosclerotic plaque formation is an exciting area of ongoing research. Target specific therapies directed at pro-inflammatory cytokines such as IL-1β, IL-6, TNFα, and CCL2 have demonstrated slowing in the progression of atherosclerosis in animal models and improved cardiovascular outcomes in human subjects. Most notably, treatment with the monoclonal antibody canakinumab, which directly targets and neutralizes IL-1β, was recently shown to be associated with reduced risk of adverse cardiovascular events compared to placebo in a randomized, placebo-controlled trial. Several other therapies including colchicine, methotrexate and leukotri...Continue Reading

Citations

May 7, 2020·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Tiefeng CaoYingqun Huang
Dec 29, 2018·Aging·Ines Colmegna, Ursula Stochaj
Apr 22, 2020·International Journal of Rheumatic Diseases·Cristian CaimmiMaurizio Rossini
Jul 1, 2020·Frontiers in Cardiovascular Medicine·Caroline Mullis, Talia H Swartz
Oct 2, 2020·Clinica Chimica Acta; International Journal of Clinical Chemistry·Yingjian DengXin Su
Jun 5, 2021·Materials Science & Engineering. C, Materials for Biological Applications·Meili ShenYapeng Li
Jun 3, 2021·International Journal of Molecular Sciences·Eunhye Ji, Sahmin Lee
Jun 25, 2021·QJM : Monthly Journal of the Association of Physicians·Yaniv HadiShaul Atar
Aug 17, 2021·Future Cardiology·Marco G Del BuonoGiampaolo Niccoli
Sep 2, 2021·Journal of Cardiovascular Translational Research·Soo Ghee YeohTheam Soon Lim
Sep 14, 2021·Frontiers in Cardiovascular Medicine·Haiming WangRan Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Related Papers

Transactions of the American Clinical and Climatological Association
Paul M Ridker
Current Opinion in Lipidology
Peter L Thompson, Stefan M Nidorf
Cardiology Clinics
Paul M Ridker, David A Morrow
© 2022 Meta ULC. All rights reserved